Rivastigmine administration during open-label extension therapy benefited patients who had progressed slowly and those who had progressed rapidly during initial double-blind placebo treatment. 3 key findings →
Design: open-label trial
Participants: 187
Evidence: high
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
62/100
✓ Peer-reviewed
alzhub usefulness score 62 out of 100.
·
Neurology
·
2001-12-01
The data suggest that engagement in leisure activities may reduce the risk of incident dementia, possibly by providing a reserve that delays the onset of clinical manifestations of the disease. 4 key findings →
Participants: 1,772
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
We report the first detailed population-based maps of cortical gray matter loss in Alzheimer's disease (AD), revealing prominent features of early structural change. 4 key findings →
Design: longitudinal study
Participants: 46
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
The association between blood pressure and dementia is debated. 4 key findings →
Design: longitudinal study
Participants: 6,668
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
The transition of microglia from the normal resting state to the activated state is associated with an increased expression of receptors known as peripheral benzodiazepine binding sites, which are abundant on cells of mononuclear phagocyte lineage. 4 key findings →
Participants: 15
Evidence: low
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
This study provides a comprehensive estimate of the excess costs that result from providing informal dementia care in the community. 3 key findings →
Design: longitudinal study
Participants: 2,043
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
The development of Alzheimer's disease (AD) later in life may be reflective of environmental factors operating over the course of a lifetime. 3 key findings →
Design: case-control study
Participants: 193
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
61/100
✓ Peer-reviewed
alzhub usefulness score 61 out of 100.
·
JAMA
·
2001-03-01
During 21 046 person-years of follow-up (median follow-up, 6.3 years), 199 women developed dementia, including 159 who developed AD. 5 key findings →
Design: cohort study
Participants: 3,601
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
The field of aging and dementia is focusing on the characterization of the earliest stages of cognitive impairment. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
61/100
✓ Peer-reviewed
alzhub usefulness score 61 out of 100.
·
Neurology
·
2001-01-01
This study examined the temporal trends in the incidence rates of HIV dementia, cryptococcal meningitis, toxoplasmosis, progressive multifocal leukoencephalopathy, and CNS lymphoma from January 1990 to December 1998 in the Multicenter AIDS Cohort Study. 3 key findings →
Design: cohort study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
The possibility that history of depression is a risk factor for dementia needs to be taken seriously and explanations of the association need to be further researched. 2 key findings →
Design: meta-analysis
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
Individuals currently characterized as having MCI progress steadily to greater stages of dementia severity at rates dependent on the level of cognitive impairment at entry and they almost always have the neuropathologic features of AD. 2 key findings →
Participants: 177
Evidence: low
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
Several studies suggested that women are at higher risk of dementia than men. 4 key findings →
Design: cohort study
Participants: 7,046
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
60/100
✓ Peer-reviewed
alzhub usefulness score 60 out of 100.
·
JAMA
·
2001-06-01
A significant portion of sleep-disordered breathing is associated with ApoE epsilon4 in the general population. 4 key findings →
Design: cohort study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
60/100
✓ Peer-reviewed
alzhub usefulness score 60 out of 100.
·
JAMA
·
2001-06-01
Our prognostic index, which used 6 risk factors known at discharge and a simple additive point system to stratify medical patients 70 years or older according to 1-year mortality after hospitalization, had good discrimination and calibration and generalized well in an independent sample of patients at a different site. 2 key findings →
Participants: 1,495
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
Median survival after the onset of dementia is much shorter than has previously been estimated. 1 key finding →
Participants: 10,263
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
60/100
✓ Peer-reviewed
alzhub usefulness score 60 out of 100.
·
Neurology
·
2001-05-01
There were insufficient data to make any recommendations regarding cognitive screening of asymptomatic individuals. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
Although numerous studies of the longitudinal course of schizophrenia have demonstrated the clinical deterioration that occurs predominantly in the early stages of the illness, the pathophysiology of this clinical phenomenon has not been established. 5 key findings →
Design: longitudinal study
Participants: 107
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Elevated midlife blood pressures, and the resulting increased white matter hyperintensities, increase the risk for MCI in a group of community-dwelling older men to at least the same degree as apolipoprotein E4 genotype. 5 key findings →
Design: longitudinal study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
59/100
✓ Peer-reviewed
alzhub usefulness score 59 out of 100.
·
Neurology
·
2001-05-01
A population-based longitudinal study in Sweden, the Kungsholmen Project A random sample of 370 nondemented persons, aged 75 years and older and not treated with B(12) and folate, was followed for 3 years to detect incident AD cases. 1 key finding →
Design: longitudinal study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
Some well-known risk factors for AD were confirmed in this study and potential new risk factors were identified. 3 key findings →
Design: longitudinal study
Participants: 36
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
We used MRI volume sampling with coregistered and atrophy corrected FDG-PET scans to test three hypotheses: 1) hippocampal formation measures are superior to temporal neocortical measures in the discrimination of normal (NL) and mild cognitive impairment (MCI); 2) neocortical measures are most useful in the separation of Alzheimer disease (AD) from NL or MCI; 3) measures of PET glucose metabolism (MRglu) have greater diagnostic sensitivity than MRI volume. 2 key findings →
Design: cross-sectional
Evidence: low
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
59/100
✓ Peer-reviewed
alzhub usefulness score 59 out of 100.
·
Neurology
·
2001-05-01
Cholinesterase inhibitors benefit patients with AD (Standard), although the average benefit appears small; vitamin E likely delays the time to clinical worsening (Guideline); selegiline, other antioxidants, anti-inflammatories, and estrogen require further study. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
This study tested role-training intervention as a way to help family caregivers appreciate and assume a more clinical belief set about caregiving and thereby ameliorate the adverse outcomes associated with caregiving. 5 key findings →
Participants: 16
Evidence: low
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
The prevalence and the degree of cerebral white matter lesions increased with age. 2 key findings →
Participants: 1,077
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor,
and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a
scientist can tell a landmark trial from a conference abstract without having to already know the
difference. Every point comes from one of 20 components, all of them printed on the study itself,
so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we
could not verify current impact factors from a source we control, and an invented one would be
worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science,
Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed
journal. A separate part scores how much the journal's own papers are cited, which tells the
tier-3 journals apart.
Two rules we don't bend. First, we never fill in a
missing value: if a record does not state a sample size or a design, that component scores
zero, and if we simply have no data for a part, such as a citation count, that part is left out and
the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed
article is capped at 16/100 and carries a warning chip — so a conference abstract or
a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not
work — above an early positive finding. Someone deciding whether to buy a supplement is served by
that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is
reproducible: the same file always yields the same numbers.
See the whole rubric drawn out →
— four charts covering all 27,380 studies: how the scores are spread and where the cap
bites, which of the 20 components the library is strong and weak on, which subjects rest on
stronger evidence, and what kinds of study each subject is actually built from.